Circa Group AS
Circa Group AS engages in the production and sale of biochemicals in Australia, France, the United Kingdom, Belgium, and Norway. The company extracts value from non-food waste biomass to produce bio-based chemicals through its Furacell production process. Its products include Cyrene, a polar aprotic solvent; and Levoglucosenone derivatives. The company's products are used in pharmaceuticals, agro… Read more
Circa Group AS (CIRCA) - Net Assets
Latest net assets as of June 2024: Nkr26.81 Million NOK
Based on the latest financial reports, Circa Group AS (CIRCA) has net assets worth Nkr26.81 Million NOK as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr39.51 Million) and total liabilities (Nkr12.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr26.81 Million |
| % of Total Assets | 67.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1.44 |
Circa Group AS - Net Assets Trend (2021–2024)
This chart illustrates how Circa Group AS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Circa Group AS (2021–2024)
The table below shows the annual net assets of Circa Group AS from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | Nkr30.06 Million | -16.57% |
| 2023-06-30 | Nkr36.03 Million | -13.69% |
| 2022-06-30 | Nkr41.74 Million | +12029.01% |
| 2021-06-30 | Nkr-349.92K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Circa Group AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2674803564.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Nkr57.01 Million | 189.64% |
| Total Equity | Nkr30.06 Million | 100.00% |
Circa Group AS Competitors by Market Cap
The table below lists competitors of Circa Group AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hummingbird Resources PLC
PINK:HUMRF
|
$3.57 Million |
|
ThreeD Capital Inc
OTCQX:IDKFF
|
$3.57 Million |
|
BH Global Corporation Limited
TW:911608
|
$3.57 Million |
|
Solara Minerals Ltd
AU:SLA
|
$3.57 Million |
|
Webcentral Group Limited
PINK:MLBEF
|
$3.57 Million |
|
BitFuFu Inc. Warrant
NASDAQ:FUFUW
|
$3.56 Million |
|
Wedia SA
PA:ALWED
|
$3.56 Million |
|
KOAS Co. Ltd
KO:071950
|
$3.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Circa Group AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 36,029,300 to 30,061,000, a change of -5,968,300 (-16.6%).
- Net loss of 5,977,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-5.98 Million | -19.88% |
| Other Changes | Nkr8.70K | +0.03% |
| Total Change | Nkr- | -16.57% |
Book Value vs Market Value Analysis
This analysis compares Circa Group AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.58x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | Nkr0.00 | Nkr0.64 | x |
| 2022-06-30 | Nkr0.34 | Nkr0.64 | x |
| 2023-06-30 | Nkr0.32 | Nkr0.64 | x |
| 2024-06-30 | Nkr0.25 | Nkr0.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Circa Group AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.88%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8920.90%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.23x
- Recent ROE (-19.88%) is below the historical average (-13.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -257.33% | 0.01x | 0.00x | Nkr-173.18K |
| 2022 | -16.77% | -758.56% | 0.02x | 1.13x | Nkr-11.17 Million |
| 2023 | -16.58% | -504.31% | 0.03x | 1.20x | Nkr-9.58 Million |
| 2024 | -19.88% | -8920.90% | 0.00x | 1.23x | Nkr-8.98 Million |
Industry Comparison
This section compares Circa Group AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $69,911,107
- Average return on equity (ROE) among peers: -132.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Circa Group AS (CIRCA) | Nkr26.81 Million | 0.00% | 0.47x | $3.57 Million |
| Arctic Bioscience AS (ABS) | $287.28 Million | -11.84% | 0.14x | $3.71 Million |
| Aqua Bio Technology ASA (ABTEC) | $8.32 Million | -176.71% | 0.95x | $7.08 Million |
| Arcticzymes Technologies ASA (AZT) | $68.08 Million | -30.08% | 0.26x | $75.20 Million |
| Circio Holding ASA (CRNA) | $-98.54 Million | 0.00% | 0.00x | $16.90 Million |
| Exact Therapeutics AS (EXTX) | $42.24 Million | -35.10% | 0.23x | $3.13 Million |
| Lytix Biopharma AS (LYTIX) | $107.89 Million | -87.37% | 0.36x | $32.92 Million |
| PCI Biotech Holding ASA (PCIB) | $57.40 Million | -95.98% | 0.11x | $440.48K |
| SoftOx Solutions AS (SOFTX) | $16.01 Million | -444.47% | 3.86x | $12.09 Million |
| Thor Medical ASA (TRMED) | $140.52 Million | -314.06% | 1.11x | $50.43 Million |